TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for α2-and α3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates

被引:166
作者
Atack, JR [1 ]
Wafford, KA [1 ]
Tye, SJ [1 ]
Cook, SM [1 ]
Sohal, B [1 ]
Pike, A [1 ]
Sur, C [1 ]
Melillo, D [1 ]
Bristow, L [1 ]
Bromidge, F [1 ]
Ragan, I [1 ]
Kerby, J [1 ]
Street, L [1 ]
Carling, R [1 ]
Castro, JL [1 ]
Whiting, P [1 ]
Dawson, GR [1 ]
McKernan, RM [1 ]
机构
[1] Neurosci Res Ctr, Merck Sharp & Dohme Res Labs, Harlow CM20 2QR, Essex, England
关键词
D O I
10.1124/jpet.105.089920
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
7-( 1,1-Dimethylethyl)-6-( 2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)3-( 2-fluorophenyl)-1,2,4-triazolo[ 4,3-b] pyridazine ( TPA023) is a triazolopyridazine that binds with equivalent high ( subnanomolar) affinity to the benzodiazepine binding site of recombinant human GABA A receptors containing an alpha 1, alpha 2, alpha 3, or alpha 5 subunit but has partial agonist efficacy at the alpha 2 and alpha 3 subtypes and essentially antagonist efficacy at the alpha 1 and alpha 5 subtypes. In rats, TPA023 gave time- and dose-dependent occupancy after oral dosing, with 50% occupancy corresponding to a dose of 0.42 mg/ kg. It has anxiolytic-like activity in unconditioned ( elevated plus maze) and conditioned ( fear-potentiated startle and conditioned suppression of drinking) rat models of anxiety with minimum effective doses ( MED; 1-3 mg/ kg) corresponding to 70 to 88% occupancy. However, there was no appreciable sedation in a response sensitivity ( chain-pulling) assay at a dose of 30 mg/ kg, resulting in 99% occupancy. Similarly, TPA023 was robustly anxiolytic in the squirrel monkey conditioned emotional response assay, with a MED of 0.3 mg/ kg, but did not produce any sedation in a lever-pressing test of sedation even at 10 mg/ kg. TPA023 produced no impairment in performance in the mouse Rotarod assay, and there was only a mild interaction with ethanol. In addition to anxiolytic-like efficacy, TPA023 had anticonvulsant activity in a mouse pentylenetetrazole seizure model. Finally, TPA023 did not cause precipitated withdrawal in mice treated for 7 days with the nonselective agonist triazolam, nor did N-methyl-beta-carboline-3- carboxamide ( FG 7142) precipitate withdrawal in mice treated for 7 days with TPA023. In summary, the novel alpha 2/alpha 3-selective efficacy profile of TPA023 translates into a nonsedating anxiolytic profile that is distinct from nonselective agonists.
引用
收藏
页码:410 / 422
页数:13
相关论文
共 40 条
[1]   The use of benzodiazepines in anxiety and other disorders [J].
Argyropoulos, SV ;
Nutt, DJ .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1999, 9 :407-412
[2]   Anxioselective Compounds Acting at the GABAA Receptor Benzodiazepine Binding Site [J].
Atack, John R. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2003, 2 (04) :213-232
[3]   Anxiogenic properties of an inverse agonist selective for α3 subunit-containing GABAA receptors [J].
Atack, JR ;
Hutson, PH ;
Collinson, N ;
Marshall, G ;
Bentley, G ;
Moyes, C ;
Cook, SM ;
Collins, I ;
Wafford, K ;
McKernan, RM ;
Dawson, GR .
BRITISH JOURNAL OF PHARMACOLOGY, 2005, 144 (03) :357-366
[4]   Regional differences in the inhibition of mouse in vivo [3H]Ro 15-1788 binding reflect selectivity for α1 versus α2 and α3 subunit-containing GABAA receptors [J].
Atack, JR ;
Smith, AJ ;
Emms, F ;
McKernan, RM .
NEUROPSYCHOPHARMACOLOGY, 1999, 20 (03) :255-262
[5]   Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders [J].
Ator, NA .
CNS SPECTRUMS, 2005, 10 (01) :31-39
[6]   Comparison of benzodiazepine (BZ) receptor agonists in two rodent activity tests [J].
Bayley, PJ ;
Bentley, GD ;
Jackson, A ;
Williamson, D ;
Dawson, GR .
JOURNAL OF PSYCHOPHARMACOLOGY, 1996, 10 (03) :206-213
[7]   Pharmacological characterization of a novel cell line expressing human α4β3δ GABAA receptors [J].
Brown, N ;
Kerby, J ;
Bonnert, TP ;
Whiting, PJ ;
Wafford, KA .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (07) :965-974
[8]   7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine:: A functionally selective γ-aminobutyric acidA (GABAA) α2/α3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models [J].
Carling, RW ;
Madin, A ;
Guiblin, A ;
Russell, MGN ;
Moore, KW ;
Mitchinson, A ;
Sohal, B ;
Pike, A ;
Cook, SM ;
Ragan, IC ;
McKernan, RM ;
Quirk, K ;
Ferris, P ;
Marshall, G ;
Thompson, SA ;
Wafford, KA ;
Dawson, GR ;
Atack, JR ;
Harrison, T ;
Castro, JL ;
Street, LJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (23) :7089-7092
[9]   An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA α5 receptors with cognition enhancing properties [J].
Chambers, MS ;
Atack, JR ;
Carling, RW ;
Collinson, N ;
Cook, SM ;
Dawson, GR ;
Ferris, P ;
Hobbs, SC ;
O'Connor, D ;
Marshall, G ;
Rycroft, W ;
MacLeod, AM .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (24) :5829-5832
[10]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099